Primary amyloidosis. Clinical, immunochemical and immunoglobulin metabolism. Studies in fifteen patients.
D000328:Adult; D000361:Agammaglobulinemia / Q000150:complications; D000686:Amyloidosis / Q000145:classification / Q000175:diagnosis* / Q000276:immunology* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D001536:Bence Jones Protein / Q000652:urine; D001853:Bone Marrow / Q000473:pathology; D001854:Bone Marrow Cells; D004586:Electrophoresis; D006474:Hemorrhagic Disorders / Q000209:etiology; D006529:Hepatomegaly / Q000209:etiology; D006801:Humans; D007122:Immunoelectrophoresis; D007074:Immunoglobulin G / Q000378:metabolism* / Q000652:urine; D007075:Immunoglobulin M / Q000378:metabolism* / Q000652:urine; D007668:Kidney / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma; D010649:Phenylalanine / Q000627:therapeutic use; D012469:Salivary Glands / Q000473:pathology; D012712:Serum Globulins; D014059:Tongue / Q000473:pathology; D014985:Xerophthalmia / Q000209:etiology; D014987:Xerostomia / Q000209:etiology
D007074:Immunoglobulin G; D007075:Immunoglobulin M; D012712:Serum Globulins; D010649:Phenylalanine; D001536:Bence Jones Protein